anx_I__cpt_1__cpt_5__cpt_1__cpt_2__text_5

Strong EU-based biomedical research will help strengthen the competitiveness of the European healthcare biotechnology, medical technology and pharmaceutical industries. EU collaboration with developing countries will allow those countries to develop research capacities. The EU must also play an active role in creating an environment conducive to innovation in public and pharmaceutical sectors which address public health needs, in particular to maximise the success of clinical research. Research-based SMEs are the main economic drivers of the healthcare biotechnology and medical technology industries. Although Europe now has more biotechnology companies than the US, most of them are small and less mature than their competitors. Public-private research efforts at the EU level will facilitate their development. EU research will also contribute to the development of new norms and standards to set up an appropriate legislative framework for new medical technologies (e.g. regenerative medicine). The global leadership of European research and innovation in the field of alternative testing strategies, in particular non-animal methods, should be ensured.

← anx_I__cpt_1__cpt_5__cpt_1__cpt_2__text_4 · All articles · anx_I__cpt_1__cpt_5__cpt_1__cpt_2__text_6 →

Source: EUR-Lex (Cellar) · retrieved 2026-11-04 · Text as adopted (Official Journal); later amendments are not incorporated in this text.